Indeed, a significant association has been observed between the increase of SREBP1 expression in clinical specimens and the lack of clinical response to neo-adjuvant endocrine therapy, providing support for a role of SREBP1-related lipogenic programs in endocrine resistance in breast cancer [15]. Here, SREBF1 is linked to breast carcinoma.